Claims

1. A pharmaceutically acceptable acid addition salt of a compound of formula I,



I

wherein

R^1 is C_{1-2} alkyl substituted with one or more fluoro substituents;

R^2 is C_{1-2} alkyl; and

n is 0, 1, or 2.

2. An acid addition salt as claimed in claim 1, wherein the acid is a sulfonic acid.

3. An acid addition salt as claimed in claim 1, wherein the acid is methanesulfonic acid, *n*-propanesulfonic acid, benzenesulfonic acid, 1,5-naphthalenedisulfonic acid, or n-butanesulfonic acid.

4. An acid addition salt as claimed in claim 1, wherein R^1 is $-OCHF_2$ or $-OCH_2CH_2F$.

5. An acid addition salt as claimed in claim 1, wherein R^2 is methyl.

6. An acid addition salt as claimed in claim 1, wherein n is 0 or 2.

7. An acid addition salt as claimed in claim 1, wherein the compound of formula I is

Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(OMe) or

Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(2,6-diF)(OMe).

8. An acid addition salt as claimed in claim 1 in substantially crystalline form.

9. An acid addition salt as claimed in claim 1 in partially crystalline form.

10. An acid addition salt as claimed in claim 8, wherein n is 0.

11. An acid addition salt as claimed in claim 9, wherein n is 2.

12. An acid addition salt as claimed in claim 10, which is Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(OMe) benzene-sulfonic acid salt, characterised by an X-ray powder diffraction pattern characterised by peaks with d-values at 5.9, 4.73, 4.09, and 4.08Å.

13. An acid addition salt as claimed in claim 11, which is Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(2,6-diF)(OMe) hemi-1,5-naphthalenedisulfonic acid salt, characterised by an X-ray powder diffraction pattern characterised by peaks with d-values at 18.3, 9.1, 5.6, 5.5, 4.13, 4.02, 3.86, 3.69, and 3.63Å.

14. A process for the preparation of an acid addition salt as claimed in any one of claims 1 to 3, which process comprises addition of an acid to a compound of formula I.

15. A process as claimed in claim 14, which process further comprises crystallising the acid addition salt.

16. A pharmaceutical formulation comprising an acid addition salt of any one of claims 1 to 3, in admixture with a pharmaceutically acceptable adjuvant, diluent, or carrier.

17. A method for treating a condition where inhibition of thrombin is required, comprising administering a therapeutically effective amount of an acid addition salt of any one of claims 1 to 3, to a person suffering from, or susceptible to, such a condition.